4-(Butylamino)butanal | 693773-13-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(Butylamino)butanal
• CAS: 693773-13-6
• 化学式: C₈H₁₇NO
• 分子量: 143.23
• InChiKey: WOMQIONTOWTKTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• [EN] BENZOHETEROCYCLIC COMPOUNDS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：WO1991005549A1

  公开（公告）日：1991-05-02

  (EN) Novel benzoheterocyclic compounds of formula (I), wherein R1 is H, halogen, alkyl, optionally substituted amino, alkoxy; R2 is H, halogen, alkoxy, phenylalkoxy, OH, alkyl, optionally substituted amino, carbamoyl-alkoxy, optionally substituted amino-alkoxy, optionally substituted benzoyloxy; R3 is a group: -NR4R5 or -CO-NR11R12; R4 is H, optionally substituted benzoyl, alkyl; R5 is a group $g(a) [R16 is halogen, optionally substituted alkyl, OH, alkoxy, alkanoyloxy, alkylthio, alkanoyl, carboxy, alkoxycarbonyl, CN, NO2, optionally substituted amino, phenyl, cycloalkyl, etc., or a group: -O-A-NR6R7; m is 0 to 3], phenyl-alkoxycarbonyl, alkanoyl, phenyl-alkanoyl, etc.; R11 is H or alkyl; R12 is cycloalkyl or optionally substituted phenyl; and W is a group: -(CH2)p (p is 3 to 5) or -CH=CH-(CH2)q (q is 1 to 3), the carbon atom of these groups being optionally replaced by 0, S, SO, SO2 or a group: -N(R13)- and further these groups having optionally 1 to 3 substituents of alkyl, alkoxycarbonyl, carboxy, OH, O, alkanoyloxy, etc., which have excellent vasopressin antagonistic activies and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.(FR) Nouveaux composés benzohétérocycliques de formule (I), dans laquelle R1 représente H, halogène, alkyle, amino éventuellement substitué, alcoxy; R2 représente H, halogène, alcoxy, phénylalcoxy, OH, alkyle, amino éventuellement substitué, carbamoyle-alcoxy, amino-alcoxy éventuellement substitué, benzoyloxy éventuellement substitué; R3 représente un groupe -NR4R5 ou -CO-NR11R12; R4 est H, benzoyle éventuellement substitué, alkyle; R5 est un groupe $g(a) [dans lequel R16 représente halogène, alkyle éventuellement substitué, OH, alcoxy, alcanoyloxy, alkylthio, alcanoyle, carboxy, alcoxycarbonyle, CN, NO2, amino éventuellement substitué, phényle, cycloalkyle, etc., ou un groupe -O-A-NR6R7; m est compris entre 0 et 3], phényl-alcoxycarbonyle, alcanoyle, phényl-alcanoyle, etc.; R11 représente H ou alkyle; R12 représente cycloalkyle ou phényle éventuellement substitué; et W est un groupe -CH2)p (p étant compris entre 3 et 5) ou -CH=CH-(CH2)q (q étant compris entre 1 et 3), l'atome de carbone de ces groupes étant éventuellement remplacé par 0, S, SO, SO2 ou un groupe -N(R13)-, ces groupes comportant éventuellement de 1 à 3 substituants d'alkyle, alcoxycarbonyle, carboxy, OH, O, alcanoyloxy, etc. Ces composés présentent d'excellentes activités antagonistes de la vasopressine et sont utiles en tant que vasodilateurs, agents hypotensifs, diurétiques et inhibiteurs d'agglutination de plaquettes. On décrit également une composition antagoniste de la vasopressine contenant ce composé en tant qu'ingrédient actif.

  新的苯并杂环化合物，其化学式为（I），其中R1为H，卤素，烷基，可选择取代的氨基，烷氧基；R2为H，卤素，烷氧基，苯基烷氧基，OH，烷基，可选择取代的氨基，氨基-卡巴莫基烷氧基，可选择取代的氨基-烷氧基，可选择取代的苯甲酰氧基；R3为一个基团：-NR4R5或-CO-NR11R12；R4为H，可选择取代的苯甲酰基，烷基；R5为一个基团$g(a) [其中R16为卤素，可选择取代的烷基，OH，烷氧基，烷酰氧基，烷硫基，烷酰基，羧基，烷氧羰基，CN，NO2，可选择取代的氨基，苯基，环烷基等，或一个基团：-O-A-NR6R7；m为0至3]，苯基-烷氧羰基，烷酰基，苯基-烷酰基等；R11为H或烷基；R12为环烷基或可选择取代的苯基；W为一个基团：-(CH2)p（p为3至5）或-CH=CH-( )q（q为1至3），这些基团的碳原子可以选择性地被0，S，SO，SO2或一个基团：-N（R13）-替换，并且这些基团还可以具有1至3个取代基，如烷基，烷氧羰基，羧基，OH，O，烷酰氧基等，具有出色的抗利尿激素拮抗活性，并且可用作扩血管剂，降压剂，利尿剂，血小板凝聚抑制剂和含有该化合物的抗利尿激素拮抗剂组合物的活性成分。
• Aromatic Compounds
  申请人：Fukushima Tae

  公开号：US20070270422A1

  公开（公告）日：2007-11-22

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，具有抑制胶原生成的优异效果，并且具有较少的副作用，在安全性方面表现出色。本发明的化合物由以下通式（1）表示：[其中X1代表氮原子或基团—CH═；R1代表基团-Z-R6，其中Z代表基团—CO—、基团—CH(OH)—或类似基团，而R6代表具有1到4个氮原子、氧原子或硫原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团；R2代表氢原子、卤素原子或低碳链基团；Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团；A代表基团或类似基团，其中R3代表氢原子、低碳醚基团或类似基团，p代表1或2，而R4代表咪唑基低碳基团或类似基团。
• HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：Sumida Takumi

  公开号：US20100261720A1

  公开（公告）日：2010-10-14

  The present invention provides a heterocyclic compound represented by General Formula (1): wherein R 1 is a group R 5 —Z 1 —, etc., Z 1 is a lower alkylene group, etc., and R 5 is a group represented by General Formula; wherein R 13 is a hydrogen atom, etc., m is an integer from 1 to 5; R 2 is a hydrogen atom: Y is CH or N: A 1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group —CO—, etc.: R 3 is a hydrogen atom, etc.: R 4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R 3 and R 4 , together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.

  本发明提供一种由通式(1)表示的杂环化合物：其中R1为R5-Z1-等基团，Z1为低碳烷基等，而R5则为通式所表示的基团；其中R13为氢原子等，m为1到5的整数；R2为氢原子；Y为CH或N；A1为选自吲哚二基基团等的杂环环；其中该杂环环可以具有至少一个取代基；T为-CO-等基团；R3为氢原子等；R4为低碳基基团，可以选择性地被一个或多个羟基取代等；R3和R4与它们所结合的氮原子一起可以结合成一个5-到10-成员的饱和杂环环，其中该杂环环可以具有至少一个取代基。本发明的杂环化合物具有抑制胶原蛋白产生和/或治疗肿瘤的优异效果。
• AROMATIC COMPOUND
  申请人：FUKUSHIMA Tae

  公开号：US20120238750A1

  公开（公告）日：2012-09-20

  The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group —Z—R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的化合物由以下通式（1）表示：[其中X1表示氮原子或基团—CH═; R1表示基团—Z—R6，其中Z表示基团—CO—、基团—CH（OH）—或类似物，而R6表示具有1至4个氮原子、氧原子或硫原子的5至15环的单环、双环或三环、饱和或不饱和的杂环基团; R2表示氢原子、卤素原子或较低的烷基链; Y表示基团—O—、基团—CO—、基团—CH（OH）—、较低的烷基链或类似物; A表示基团或类似物，其中R3表示氢原子、较低的烷氧基或类似物，p表示1或2，而R4表示咪唑基较低的烷基链或类似物。